Avallone A, Aloj L, Pecori B, et al. - A total of 61 persons treated in a nonrandomized phase II study (BRANCH) with concomitant or sequential (4 d prior to chemoradiotherapy) administration of bevacizumab with preoperative chemoradiotherapy were involved in order to prospectively assess the value of ¹⁸F-FDG PET/CT done during and following preoperative chemoradiotherapy with bevacizumab for the prognostication of complete pathologic tumor regression and survival in persons with MRI-defined high-risk locally advanced rectal cancer. Results imply that early metabolic response could function as a surrogate marker of the advantage of antiangiogenic therapy. In the preoperative treatment of people with locally advanced rectal cancer, the use of early ¹⁸F-FDG PET/CT assessment to prognosticate pathologic response and survival was supported additionally by the findings. Moreover, in prognosticating tumor regression, ΔTLG-early exhibited superior exactitude and it could be especially beneficial in guiding treatment-modifying decisions during preoperative chemoradiotherapy on the basis of the expected response.